ArticleAnnals of clinical and translational neurology2015
CSF beta-amyloid 1-42 - what are we measuring in Alzheimer's disease?
Article in Annals of clinical and translational neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 38 citations in OpenAlex.
- CSF Cytokines in Aging, Multiple Sclerosis, and Dementia.Frontiers in immunology · 2019Trial
- Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers.Alzheimer's research & therapy · 2017Trial
- Functional discrimination of CSF from Alzheimer's patients in a brain on chip platform.Scientific reports · 2025Article
- Relationships of Cognitive Measures with Cerebrospinal Fluid but Not Imaging Biomarkers of Alzheimer Disease Vary between Black and White Individuals.Annals of neurology · 2024Article
- Charting the Next Road Map for CSF Biomarkers in Alzheimer's Disease and Related Dementias.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Review
- Tracers progress for positron emission tomography imaging of glial-related disease.Journal of biomedical research · 2022Article
- Cross-species metabolomic analysis of tau- and DDT-related toxicity.PNAS nexus · 2022Article
- Article
- Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease.Journal of internal medicine · 2021Review
- Plasma contact factors as novel biomarkers for diagnosing Alzheimer's disease.Biomarker research · 2021Article
- Body Fluid Biomarkers for Alzheimer's Disease-An Up-To-Date Overview.Biomedicines · 2020Review
- Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer's Disease.International journal of molecular sciences · 2020Review
- Race modifies default mode connectivity in Alzheimer's disease.Translational neurodegeneration · 2020Article
- High-resolution metabolomic profiling of Alzheimer's disease in plasma.Annals of clinical and translational neurology · 2020Article
- Towards a unified protocol for handling of CSF before β-amyloid measurements.Alzheimer's research & therapy · 2019Article
- Linked CSF reduction of phosphorylated tau and IL-8 in HIV associated neurocognitive disorder.Scientific reports · 2019Article
- Pharmacological Potential of Cilostazol for Alzheimer's Disease.Frontiers in pharmacology · 2019Review
- Amyloidogenic Nanoplaques in Blood Serum of Patients with Alzheimer's Disease Revealed by Time-Resolved Thioflavin T Fluorescence Intensity Fluctuation Analysis.Journal of Alzheimer's disease : JAD · 2019Article
- Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.Alzheimer's research & therapy · 2018Article
- Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo characterize biological and technical factors which influence cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarker levels, including the presence of apolipoprotein E (APOE) ε4 allele, AD diagnosis, Aβ-binding proteins, sample processing, and preanalytical handling.
methodsCSF was collected from 140 subjects with normal cognition, mild cognitive impairment, AD, and non-AD dementia. CSF levels of beta-amyloid 1-42 (Aβ42), total Tau (t-Tau), and Tau phosphorylated at threonine 181 (p-Tau181) were analyzed following the standard and modified protocols. CSF levels of apoJ, apoE, albumin, and α-synuclein were measured in a subgroup (n = 69), and their effects on measured AD biomarker levels were also determined in vitro using human CSF samples.
resultsCSF Aβ42 levels measured using the AD Neuro-imaging Initiative (ADNI) protocol (which we call suspended Aβ42 or susAβ) were lower than total measurable CSF Aβ42 in all groups, and on average represents 57% of the latter. Logistic regression analysis showed this proportion (% susAβ) to be directly correlated with CSF Aβ42 and apoJ levels, but inversely correlated with CSF t-Tau levels. Finally, we showed in vitro that increasing apoE and apoJ levels directly increased % susAβ.
conclusionCSF susAβ levels are influenced by biological and technical factors, and may represent a marker of Aβ susceptible to lipoprotein-mediated clearance. Clinical trials should include total measurable Aβ42 and susAβ to better inform outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.